The Valve Wire

Executive Summary

Today's biggest story in structural heart comes from JACC, where the Tricuspid Valve Academic Research Consortium (TVARC-2) publishes its second consensus document — a landmark framework for designing future tricuspid valve trials that will shape how we compare emerging technologies, surgery, and medical therapy for years to come. Meanwhile, Edwards Lifesciences reports Q1 2026 earnings tomorrow with Wall Street closely watching TAVR volume growth and TMTT platform adoption, and a large Norwegian registry study reveals women derive significantly greater long-term survival benefit from TAVI than men. In the transcatheter mitral space, case reports highlight both the expanding reach of TEER into unconventional clinical scenarios and its complications — including leaflet tears and clip embolization — reminding us that device maturity doesn't eliminate procedural hazard.

For the clinical audience: the TVARC-2 publication (Davidson, Hahn, Mehaffey, Cohen, Pinney et al. in JACC) arrives at a pivotal moment — just months after the ESC/EACTS 2025 guidelines elevated transcatheter tricuspid intervention to Class IIa, and with both TriClip and EVOQUE now FDA-approved. The document standardizes trial design and endpoint selection for the next generation of head-to-head comparisons, a critical infrastructure step given how rapidly this space is evolving. Elsewhere, the SAVER amyloidosis screening study offers a practical, multi-organ screening algorithm for cardiac amyloidosis in AS patients heading to TAVI/SAVR — a growing clinical need. A retrospective database study suggests GLP-1 receptor agonists may dramatically reduce MACE in TAVR patients with diabetes or obesity, though the usual caveats about retrospective, database-derived effect sizes apply. And an RCT of virtual reality-augmented TAVI planning from Düsseldorf shows improved 3D understanding and reduced access-site bleeding — a modest but tangible procedural benefit.

---

Today's Key Findings

[NOTABLE] TVARC-2 Consensus: Tricuspid Valve Trial Design and Endpoints — Published in JACC, this second TVARC document (Davidson CJ, Hahn RT, Mehaffey JH, Cohen DJ, Pinney SP et al.) establishes standardized trial design principles and endpoint definitions for comparing transcatheter tricuspid valve interventions with surgery and medical therapy. Building on TVARC-1's disease classification framework, TVARC-2 addresses a critical gap: how to conduct rigorous, comparable trials in a space where FDA has now approved both TEER (TriClip) and replacement (EVOQUE) technologies. The inclusion of Mehaffey — a surgeon who has written critically about therapies outpacing evidence — among the authors signals a serious attempt at balanced, clinically grounded trial architecture. This document is particularly important given the ESC 2025 upgrade of transcatheter TR treatment to Class IIa (LOE A), which was based on trials (TRILUMINATE, Tri.Fr, TRISCEND II) that varied considerably in endpoint selection and patient populations. Standardization here will be essential for the next wave of device-vs-device and device-vs-surgery comparisons.

[NOTABLE] SAVER Study: A Holistic Amyloidosis Screening Algorithm for Aortic Stenosis Patients — Published in the European Journal of Preventive Cardiology, this prospective cohort study enrolled 1,001 AS patients scheduled for TAVI or SAVR and applied a systematic, multi-organ symptom-based screening approach for cardiac amyloidosis (CA). The screen flagged 40% of patients for further evaluation; ultimately 2% had confirmed CA — consistent with prior prevalence estimates. Key predictors included male sex (OR 23.8), carpal tunnel syndrome (OR 5.5), spinal stenosis (OR 4.1), and sparkling myocardium (OR 4.8). The optimized model achieved an AUC of 0.88. This is clinically actionable: identifying CA before valve intervention can prevent futile procedures and redirect patients toward disease-modifying therapies (tafamidis, patisiran). The editorial piece from Magouliotis et al. published the same day in the Hellenic Journal of Cardiology makes a complementary argument for a structured post-diagnosis action pathway in ATTR-positive TAVI patients — collectively, these papers argue that amyloidosis screening should become routine in the pre-TAVI workup.

TAVI-NOR Registry: Women Have Better Long-Term Survival After TAVI — In 600 consecutive patients from this Norwegian registry (Heart, Lung & Circulation), propensity-matched women had significantly better long-term event-free survival than men (HR 0.66, 95% CI 0.49–0.88, P = 0.004), with the most pronounced survival difference at 3 years (92% vs 84%). Women were older at presentation, had higher LVEF, more hypertensive heart disease, and less AF — a phenotype consistent with the known sex-based differences in AS pathophysiology. While intriguing, this is observational and the "female survival advantage" post-TAVI has been reported before; whether it reflects biology, referral patterns, or competing-risk differences remains debated.

GLP-1 Receptor Agonists and TAVR Outcomes — This retrospective TriNetX database study (Canadian Journal of Cardiology) of 3,416 propensity-matched TAVR patients with diabetes or obesity found GLP-1 RA use associated with dramatically lower MACE (HR 0.63), all-cause mortality (HR 0.61), and heart failure exacerbation (HR 0.38). The effect sizes are strikingly large — perhaps implausibly so for a database study with inherent healthy-user bias, residual confounding, and no adjudication of endpoints. GLP-1 RAs are clearly a hot area in cardiovascular medicine, but these results need prospective validation before changing practice. They do, however, generate a compelling hypothesis for a dedicated RCT in the TAVR population.

Virtual Reality-Augmented TAVI Planning: An RCT — Published in Circulation: Cardiovascular Imaging, this single-center, prospective randomized trial from Düsseldorf enrolled 140 patients and compared standard CT-based planning (3mensio) with VR-supplemented planning. VR was superior for 3D understanding, depth perception, and visualization of plaques and iliofemoral tortuosity. While no significant differences emerged in procedural data or hospital stay, the VR group had significantly lower access-site bleeding (P < 0.05). A modest but real benefit — and an early signal that immersive visualization tools may improve procedural safety beyond the current planning paradigm.

---

Aortic Valve (TAVR/TAVI)

Leadless Pacemakers After TAVI: MITAVI Study Results

The MITAVI prospective study (Archives of Cardiovascular Diseases) reports 1-year outcomes of 102 patients who received leadless pacemakers (Medtronic Micra) after developing high-grade AV block post-TAVI across four French centers. The results are encouraging: only 2 major complications (1 tamponade, 1 device migration), a 12% all-cause death rate (consistent with this elderly, comorbid population), and <1% need for upgrade to transvenous pacing. Notably, 38% of patients recovered AV conduction — underscoring the often-transient nature of post-TAVI conduction disturbances and raising the perennial question of whether we implant pacemakers too liberally in this population. The avoidance of transvenous leads eliminates the risk of lead-related tricuspid regurgitation, a meaningful consideration given the growing recognition of iatrogenic TR as a clinical problem.

Frailty and TAVI Outcomes: Australian Registry Data

This multicenter Australian registry study (Critical Care and Resuscitation) of 3,917 TAVI patients admitted to ICU found that frailty — assessed by the Clinical Frailty Scale — was independently and powerfully associated with reduced survival. Four-year survival was 73.4% for nonfrail, 62.7% for mildly frail, and 44.2% for moderately-to-severely frail patients (aHR 2.23). While the findings are unsurprising, they reinforce the importance of routine frailty assessment in TAVI decision-making. Both ACC/AHA 2020 and ESC 2025 guidelines emphasize shared decision-making and life expectancy estimation — frailty scoring is one of the most practical tools we have for this purpose, yet it remains inconsistently applied.

CT-Derived Septal Thickness Predicts Pacemaker Need in RBBB Patients

A retrospective study of 66 TAVR patients with preexisting RBBB (International Journal of Cardiology: Heart & Vasculature) found that basal interventricular septal thickness measured on pre-procedural CT at 2 mm below the membranous septum independently predicted permanent pacemaker implantation. Thinner septum (<4.35 mm) was associated with significantly higher PPI risk (AUC 0.91). Small sample, single-center, but the concept is biologically plausible: less myocardial tissue means less protection for the conduction system during valve deployment. If validated, this is the type of simple, measurable CT parameter that could refine pre-procedural risk stratification.

Cerebral Oxygenation Predicts Long-Term Mortality After TAVI

A retrospective Japanese study (Journal of Anesthesia) of 301 consecutive TAVI patients found that post-anesthetic regional cerebral oxygen saturation (rScO₂) was independently associated with both 1-year and 3-year mortality. The cutoff values (55.25 and 57.75 respectively) integrate multiple periprocedural factors — hemoglobin, renal function, BNP, hypotension, and anesthesia duration — into a single physiologic measure. While early-stage evidence, rScO₂ monitoring is widely available and could eventually serve as a real-time risk marker during TAVI procedures.

Case Reports and Technical Innovations

Transapical TAVI in LV Apical Aneurysm — A first-reported case of transapical TAVI performed through a fibrosed LV apical aneurysm after failed transfemoral access in a patient with bicuspid AS and advanced cardiomyopathy. A 29 mm SAPIEN S3 Ultra was successfully implanted. While anecdotal, this challenges the assumption that apical aneurysm is an absolute contraindication to the transapical approach.

Late Sinus of Valsalva Sequestration — JACC Case Reports describes a rare complication: an 82-year-old woman developed NSTEMI 3 months after uncomplicated TAVR due to sinus sequestration causing partial left coronary obstruction. She required CABG. Only the second reported case in a native aortic annulus — a reminder that coronary risk doesn't end with the procedure and that post-TAVI chest pain should prompt CT evaluation. This case connects directly to the ESC 2025 emphasis on lifetime management planning and CT-based anatomical analysis at the index procedure.

Physiology-Guided Coronary Protection During TAVR — An FFR-based approach to managing high-risk coronary anatomy during TAVR. After valve deployment with ambiguous angiographic findings, dynamic FFR monitoring consistently showed values above the ischemic threshold, safely avoiding chimney stenting. A case for physiologic rather than purely anatomic decision-making in the cath lab.

SESAME in Asia-Pacific — First reported experience with Septal Scoring Along the Midline Endocardium (SESAME) transcatheter septal reduction in Asia-Pacific. Four cases across diverse indications including standalone HOCM treatment and adjunctive use with TAVR for concomitant AS and septal hypertrophy. All successful, though 1 patient required permanent pacemaker.

TAVR for Bicuspid AS with 88° Horizontal Heart and Ascending Aortic Dilation — An extreme-anatomy case highlighting TAVR feasibility in an elderly patient with bicuspid valve, severe horizontal aortic root angulation, and 60 mm ascending aortic aneurysm. While the aortic aneurysm would traditionally mandate surgery, the combined procedural risk favored TAVR. Both guidelines classify TAVI for BAV as Class IIb — cases like this push the anatomical envelope and should be interpreted cautiously.

Predictors of Noncoaxial TAVR Deployment

This study in Structural Heart introduces a novel measurement technique for anteroposterior axial angle in balloon-expandable TAVR. Noncoaxial pre-deployment valve position and specific fluoroscopic coplanar angles were independent predictors of noncoaxial placement. A predictive heatmap visualization was developed — an interesting fusion of imaging science and procedural planning.

Basic Science: Toward Pharmacotherapy for Calcific Aortic Valve Disease

Chinese researchers identified chipericumin D (Chinese Journal of Natural Medicines), a natural compound from Hypericum monogynum, as an inhibitor of aortic valve interstitial cell calcification via the EGFR/PI3K/AKT pathway. Pre-clinical, but worth tracking — no approved pharmacotherapy exists for CAVD, and identification of EGFR as a potential therapeutic target adds to the growing pipeline of anti-calcification candidates.

---

Mitral Valve (MitraClip, PASCAL, TMVR)

Mitral Leaflet Tear After TEER: Mechanistic Insights

Amsalem et al. in The Canadian Journal of Cardiology present a case series on mitral leaflet tears following transcatheter edge-to-edge repair. While no abstract is available, leaflet tear is a recognized and feared TEER complication that can convert a controlled procedure into an emergency. Understanding the mechanism — whether related to calcification, leaflet tissue quality, clip positioning, or excessive tension — is essential as TEER indications expand. This publication is particularly timely as ESC 2025 upgraded TEER for ventricular secondary MR to Class I and TEER for primary MR remains Class IIa for high-surgical-risk patients. Complication transparency is critical for balanced patient counseling.

TEER in Congenital Heart Disease

Funaki et al. (Cardiovascular Intervention and Therapeutics) describe the feasibility of mitral TEER in adults with surgically repaired congenital heart disease, drawn from the OCEAN-mitral registry. This niche but growing population — adults with repaired congenital lesions who develop mitral regurgitation decades after their index surgery — represents a particularly high-risk surgical cohort where transcatheter options may be especially valuable.

TEER Beyond Traditional Contraindications

A case from JACC Case Reports describes TEER in a 52-year-old patient with degenerative MR complicated by non-bacterial thrombotic endocarditis (NBTE) and recurrent cerebral infarctions. NBTE is traditionally considered a contraindication to TEER. The team used concomitant carotid embolic protection to mitigate stroke risk during the procedure, successfully reducing MR and creating a bridge to future surgical replacement. Creative, but the off-label nature of this approach and single-patient experience warrant extreme caution before generalization.

CT Augments TEER Planning When Echo Falls Short

JACC Case Reports presents a case where severe mitral leaflet calcification rendered standard TEE-based TEER planning inadequate. Cardiac CT provided the detailed anatomical characterization needed for successful procedural planning and execution. As TEER is increasingly applied to complex degenerative mitral disease with calcification, multimodality imaging — particularly CT — becomes essential. This aligns with the broader trend toward CT-based valve planning highlighted in the Heart Valve Collaboratory's updated imaging framework.

Free-Floating Clip Retrieval in Giant Left Atrium

JACC Case Reports describes retrieval of an embolized DragonFly TEER clip from a giant left atrium (10 cm AP diameter). After active "chasing" failed due to jet-driven erratic device motion, the operators developed a passive capture strategy, stationing a snare at a fluoroscopically identified "impact zone" on the lateral atrial wall. Creative problem-solving for a catastrophic complication — but device embolization during TEER, while rare, underscores the real-world procedural risk that can be underappreciated in trial-based enthusiasm.

---

Tricuspid Valve (TriClip, TTVR)

TVARC-2: Standardizing the Future of Tricuspid Trials

[NOTABLE] The TVARC-2 publication in JACC deserves extended discussion. The tricuspid space has evolved from a therapeutic orphan to an arena with multiple FDA-approved and CE-marked devices in just 5 years. But this rapid growth has created a trial standardization problem: TRILUMINATE Pivotal, Tri.Fr, and TRISCEND II used different primary endpoints, different TR grading systems, and different comparator arms, making cross-trial comparison difficult. TVARC-2 addresses this by defining specific trial design options for technology-vs-technology, technology-vs-surgery, and technology-vs-medical therapy comparisons. The ESC 2025 guidelines placed transcatheter TR treatment at Class IIa (LOE A) — but the "A" level of evidence is based on a limited number of trials with relatively short follow-up. TVARC-2's standardization framework is the scaffolding needed for the next generation of evidence that will determine whether these therapies maintain or expand their guideline standing.

Anatomy-Based Tricuspid Repair Beyond Annuloplasty

Arai and Grau in EJCTS publish a comprehensive review unifying surgical tricuspid repair strategies — edge-to-edge repair, leaflet augmentation, papillary muscle relocation, annular repositioning — into a practical anatomical framework. This is important context for the transcatheter vs. surgical debate: while transcatheter options are rapidly expanding, surgical repair offers a broader armamentarium for addressing the full spectrum of RV-dependent tricuspid pathology. The review explicitly notes that these approaches "can rival evolving transcatheter options" — a reminder that surgical innovation continues in parallel, and that the optimal approach remains patient-specific.

TTVR Real-World Outcomes in the News

Medical Dialogues reports on the STS/ACC TVT Registry analysis of transcatheter tricuspid valve replacement (TTVR), covering 1,034 real-world EVOQUE procedures with 98.4% implantation success, 3.1% 30-day mortality, and significant functional improvement (82.7% NYHA I/II, +22.4 KCCQ-OS points). These registry data mirror the TRISCEND II pivotal results — reassuring for real-world generalizability, but follow-up remains short and the patient population is highly selected. Long-term durability and the balance of bleeding/pacemaker complications vs. symptom benefit will be critical to track.

---

Surgical vs. Transcatheter Comparisons

No new head-to-head comparison studies were published today, but several items bear on this ongoing debate:

The letter in Annals of Thoracic Surgery by Huang et al. ("Unmeasured Confounders and Interpretational Nuances in TAVR Comparisons Among Young Adults") addresses methodological concerns in TAVR vs. SAVR comparisons in younger populations — a critical issue given the ESC 2025 threshold of 70 years for TAVI preference vs. ACC/AHA's 80-year cutoff. While no abstract is available, the title alone signals ongoing skepticism about extending TAVR to younger, lower-risk patients — echoing concerns raised by Badhwar and others about therapies outpacing evidence. The 65–70 age zone remains the most contested territory in structural heart disease.

The SAVI-AVR trial protocol published in the Journal of Cardiothoracic Surgery outlines a prospective non-randomized comparison of sutureless aortic valve replacement vs. stented biological valve replacement in patients at risk for severe valve obstruction. This is a surgical-vs-surgical comparison, but it addresses the important question of how to optimize outcomes in the surgical population — particularly relevant for patients <70 where both guidelines still favor SAVR.

The anatomy-based tricuspid repair review (Arai and Grau, noted above) explicitly positions surgical repair as a competitor to transcatheter approaches, arguing that the surgical armamentarium — when fully deployed — can match or exceed transcatheter outcomes for complex RV-dependent TR. This claim needs head-to-head data, and TVARC-2's endpoint standardization should facilitate exactly such comparisons.

---

Device & Technology

The CLEAR Technique for BASILICA — Published in JACC Case Reports, this describes a novel approach (Chordal-zone Free Externalization of Retrograde Wire) for wire externalization during BASILICA procedures to prevent coronary obstruction in valve-in-valve TAVR. By using a steerable microcatheter to direct the wire retrogradely from below the aortic valve, the technique avoids deep LVOT penetration and reduces chordal entrapment risk. Successfully performed in 3 patients, with one chordal entrapment detected and corrected without complication. BASILICA has become essential for high-risk valve-in-valve procedures — simplifying it could expand access.

Piezo1-Mediated Cardiac Morphogenesis — In Science Advances, researchers uncover a mechanotransduction pathway (Piezo1 → calmodulin → Aqp8a.1) driving endocardial cell volume regulation during cardiac valve formation in zebrafish. Basic science, but a fascinating window into the developmental biology of heart valves — understanding how valves form may eventually inform how we design them.

---

Industry & Market

Medtronic leads $100M investment in artery denervation company (Cardiovascular Business). While not directly structural heart, this reflects Medtronic's broader cardiovascular portfolio strategy. With the Evolut platform facing increasing competition from Edwards' SAPIEN series and newer entrants like Anteris's DurAVR, Medtronic is diversifying its CV investment thesis. The company's structural heart pipeline includes the Intrepid TMVR system (still recruiting for its pivotal trial) and the Evolut FX+ platform.

Cedars-Sinai touts success of heart valve procedure (Beverly Press). While details are limited, Cedars-Sinai remains one of the highest-volume structural heart programs in the US and a key opinion leader site for both TAVR and mitral interventions.

---

Financial Analysis

The structural heart sector enters a pivotal week with Edwards Lifesciences (EW) reporting Q1 2026 earnings tomorrow (April 23). Wall Street is focused on three questions: (1) TAVR procedure volume growth — particularly whether the EARLY TAVR-driven expansion into asymptomatic AS is translating to commercial uptake; (2) TMTT platform trajectory — PASCAL system adoption for mitral and tricuspid repair and EVOQUE replacement adoption; and (3) the impact of the ESC 2025 guideline changes, which expanded the TAVI-eligible population by lowering the age threshold to 70 in Europe.

Edwards' stock rose 2.28% to $81.53 today, suggesting cautious optimism heading into the report. Consensus estimates peg EPS at $0.73 on revenue of $1.60 billion. The company trades at a forward P/E of 24.56 — a premium reflecting structural heart market leadership but also pricing in growth expectations. Multiple financial outlets are previewing the earnings with emphasis on the TAVR/TMTT growth narrative, and institutional interest remains strong (Universal Beteiligungs acquired 21,165 additional shares today).

Boston Scientific (BSX) surged nearly 9% on the back of its Q1 2026 results showing net sales hitting $5.2 billion. While BSX's structural heart exposure is more limited than Edwards' or Abbott's (ACURATE neo2 in TAVR, WATCHMAN in LAA closure), the company is an increasingly relevant player in the EP and interventional cardiology adjacencies that intersect structural heart care. The strong quarter demonstrates broad cardiovascular procedure volume health.

The overall medtech backdrop remains challenged by tariff uncertainty and macroeconomic headwinds — Abbott (ABT) is down 26.6% over six months and Medtronic (MDT) down 10.3%, reflecting broader sector pressure beyond structural heart-specific fundamentals. Abbott's decline is particularly notable given its dominant position in TEER (MitraClip) and tricuspid TEER (TriClip) — the TriClip FDA approval and TRILUMINATE data should be commercially tailwinds, suggesting the sell-off is driven by ex-structural heart concerns (tariffs, China exposure, diagnostics headwinds).

---

Valve Industry Stocks

Edwards Lifesciences (EW)

• Close: $81.53 | Daily Change: +$1.82 (+2.28%)
• 6-Month Performance: +6.53% ($76.53 → $81.53)
• Market Cap: $47.4B | P/E (trailing): 45.04 | P/E (forward): 24.56 | Beta: 0.94
• 52-Week Range: $72.30 – $87.89
• Analyst Consensus Target: $96.33 (range: $84 – $110, 27 analysts) — Buy
• Next Earnings: April 23, 2026 (tomorrow) | EPS est: $0.73 | Rev est: $1.60B
• Commentary: All eyes on tomorrow's report. Edwards is the structural heart bellwether, and Q1 will reveal early commercial impact of ESC 2025 guideline changes in Europe, EARLY TAVR-driven expansion in the US, and ramp of PASCAL/EVOQUE in TMTT. The stock has been range-bound between $74–$88 over six months — a decisive beat or miss could break the range. Q4 2025 saw an EPS miss but shares still climbed on positive investor sentiment around the TMTT growth story. The forward P/E of 24.56 vs. trailing 45.04 reflects expected significant earnings acceleration.

Medtronic (MDT)

• Close: $83.22 | Daily Change: +$1.22 (+1.49%)
• 6-Month Performance: -10.29% ($92.76 → $83.22)
• Market Cap: $106.8B | P/E (trailing): 23.25 | P/E (forward): 13.73 | Beta: 0.76
• 52-Week Range: $79.93 – $106.33
• Analyst Consensus Target: $109.08 (range: $91 – $121, 25 analysts) — Buy
• Next Earnings: June 3, 2026 | EPS est: $1.56 | Rev est: $9.62B
• Commentary: MDT continues its 6-month slide, now sitting near the bottom of its 52-week range. The structural heart segment (Evolut FX/FX+ TAVR, Intrepid TMVR in development) faces competitive pressure from Edwards. Today's $100M denervation investment signals portfolio diversification beyond valve therapy. The Intrepid TMVR pivotal trial continues recruiting (1,056 target enrollment) — a potential game-changer if successful, but TMVR remains one of the most technically challenging transcatheter procedures. Forward P/E of 13.73 suggests the market sees MDT as undervalued relative to earnings — a potential value play if structural heart execution improves.

Abbott (ABT)

• Close: $91.70 | Daily Change: -$1.02 (-1.10%)
• 6-Month Performance: -26.59% ($124.92 → $91.70)
• Market Cap: $159.3B | P/E (trailing): 25.69 | P/E (forward): 15.12 | Beta: 0.78
• 52-Week Range: $91.59 – $139.06
• Analyst Consensus Target: $119.48 (range: $106 – $143, 25 analysts) — Buy
• Next Earnings: July 16, 2026 | EPS est: $1.28 | Rev est: $12.54B
• Commentary: Abbott's steep decline over 6 months (sitting at its 52-week low today at $91.59) belies arguably the strongest structural heart portfolio in the industry: MitraClip (now upgraded to Class I for ventricular SMR by ESC 2025), TriClip (FDA-approved via TRILUMINATE), and a growing pipeline. The sell-off appears driven by non-structural-heart headwinds — tariff exposure, diagnostics segment concerns, and broader medtech de-rating. The 30%+ gap between current price and analyst consensus target ($119.48) represents either a significant opportunity or a market signaling structural concerns not yet reflected in analyst models.

Boston Scientific (BSX)

• Close: $64.87 | Daily Change: +$5.35 (+8.99%)
• 6-Month Performance: -36.64% ($102.39 → $64.87)
• Market Cap: $96.4B | P/E (trailing): 27.14 | P/E (forward): 16.97 | Beta: 0.78
• 52-Week Range: $59.39 – $109.50
• Analyst Consensus Target: $95.75 (range: $69 – $112, 32 analysts) — Strong Buy
• Next Earnings: July 22, 2026 | EPS est: $0.79 | Rev est: $5.17B
• Commentary: Today's nearly 9% surge follows Q1 2026 results showing $5.2B in net sales. BSX's structural heart exposure centers on the ACURATE neo2 TAVR platform and WATCHMAN FLX in LAA closure, with growing relevance in the EP adjacency to structural heart procedures (particularly AF ablation concomitant with valve interventions). The strong buy consensus from 32 analysts and 47% gap to target make BSX the most heavily discounted name in the space.

Anteris Technologies (AVR.AX)

• Close: A$7.56 | Daily Change: -A$0.34 (-4.30%)
• 6-Month Performance: -14.09% (A$8.80 → A$7.56)
• Market Cap: A$0.8B | P/E (forward): -3.47 (pre-revenue) | Beta: 0.55
• 52-Week Range: A$4.68 – A$9.79
• Analyst Target: A$13.00 (1 analyst)
• Commentary: Anteris continues to trade on pipeline potential — the DurAVR transcatheter heart valve, utilizing ADAPT tissue technology, is in its pivotal clinical trial (NCT07194265, recruiting, 1,650 patients, randomized against SAPIEN and Evolut). Today's 4.3% decline appears to reflect general small-cap medtech volatility rather than company-specific news. The DurAVR thesis rests on potentially superior hemodynamics and durability from single-piece bovine pericardial construction — a differentiated approach, but the pivotal trial results are likely years away.

Private Companies to Watch: JenaValve Technology (aortic regurgitation TAVR — the only transcatheter option specifically designed for AR, a Class IIb indication in ESC 2025), J Valve Technology (China-based, similar AR focus), and Meril Life Sciences (Myval balloon-expandable THV, demonstrated noninferiority in the LANDMARK trial) remain private. All three are positioned in niches that the major players haven't fully addressed.

Market Outlook: The structural heart medtech sector is experiencing a paradox: clinical momentum is arguably the strongest it has ever been — multiple FDA approvals, guideline upgrades, expanding indications — yet stock prices for the major players are significantly below their 52-week highs. This disconnect reflects macro headwinds (tariffs, recession fears, sector rotation) rather than structural heart fundamentals. Edwards' earnings tomorrow will be the first major data point of Q1 and could set the tone for the sector. The key number to watch isn't just TAVR volume — it's TMTT revenue growth, which will signal whether the mitral and tricuspid platform transitions are translating from clinical milestones to commercial reality.

---

Clinical Trial Updates

Aortic Valve

• [LANDMARK] Evolut Low Risk — Long-Term Follow-Up (NCT02701283)
  • Status: Active, not recruiting | Enrollment: 2,223 | Sponsor: Medtronic Cardiovascular
  • Significance: Long-term follow-up of the landmark self-expanding TAVR vs. SAVR trial in low-risk patients. Key data informing the TAVR-vs-surgery debate in younger patients. ESC 2025 used these data to support TAVI from age 70; the next readout will be critical for assessing valve durability beyond 5 years.
  • Last updated: 2026-03-19
• DurAVR Pivotal Trial (NCT07194265)
  • Status: Recruiting | Enrollment: 1,650 | Sponsor: Anteris Technologies
  • Randomized comparison of DurAVR THV against SAPIEN and Evolut series. The largest ongoing pivotal trial for a novel TAVR platform.
  • Last updated: 2026-04-22
• ULTRA-EVOLUT RCT (NCT07545369) — New trial
  • Status: Not yet recruiting | Phase: N/A | Enrollment: 200 | Sponsor: Assiut University
  • Head-to-head comparison of SAPIEN 3 Ultra Resilia vs. Evolut FX. A device-vs-device RCT that could inform platform selection, particularly relevant as both systems compete for the expanding low-risk TAVR population.
  • Last updated: 2026-04-22
• TAVI in Cardiogenic Shock (TACTICS) (NCT06638268)
  • Status: Recruiting | Enrollment: 30 | Sponsor: Rigshospitalet, Denmark
  • Comparing acute vs. stabilization-then-subacute TAVI in AS with cardiogenic shock — addressing a critically important clinical question at the extreme end of the risk spectrum.
  • Last updated: 2026-04-22
• ECHO-TAVR (NCT07317804)
  • Status: Not yet recruiting | Phase: 4 | Enrollment: 212 | Sponsor: China National Center for Cardiovascular Diseases
  • Echo-guided vs. fluoroscopy-guided TAVR — exploring whether TAVR can be performed without fluoroscopy, potentially expanding access and reducing radiation exposure.
  • Last updated: 2026-04-21
• Conestat Alfa for Cerebral/Renal Protection Post-TAVI (NCT05145283)
  • Status: Completed | Phase: 2 | Enrollment: 141 | Sponsor: University Hospital Basel
  • C1 esterase inhibitor for preventing ischemic events post-TAVI. Results pending publication — a novel pharmacologic neuroprotection strategy.
  • Last updated: 2026-04-22
• RAFT-TAVR PACE (NCT06857201) — Status change: WITHDRAWN
  • Left bundle branch area pacing vs. RV pacing post-TAVR. This trial was withdrawn before enrollment — a setback for evaluating optimal pacing strategies in post-TAVR conduction disturbances. The question remains important and unanswered.
  • Last updated: 2026-04-21
• Alternative Peripheral TAVI Accesses (NCT07539909)
  • Status: Not yet recruiting | Enrollment: 600 | Sponsor: Medical University of Silesia
  • Registry of alternative access TAVI procedures — relevant given that non-transfemoral access remains necessary in 5-15% of cases.
  • Last updated: 2026-04-20
• COMFORT Study (Coronary Re-engagement After TAVR) (NCT05779787)
  • Status: Recruiting | Enrollment: 100 | Sponsor: Niguarda Hospital
  • Aligned vs. random commissural alignment during TAVR — addresses the lifetime management concern highlighted in ESC 2025 regarding future coronary access.
  • Last updated: 2026-04-16
• INFLATE Study (Novel PTV Balloon) (NCT06816485)
  • Status: Recruiting | Enrollment: 93 | Sponsor: Biosensors Europe SA
  • Evaluating a novel balloon for percutaneous transcatheter valvuloplasty in severe AS.
  • Last updated: 2026-04-16
• Dexmedetomidine vs. Propofol/Remifentanil for TAVI Sedation (NCT07532733)
  • Status: Not yet recruiting | Enrollment: 80 | Sponsor: Erasme University Hospital
  • Respiratory and hemodynamic effects of sedation strategy during TAVI — relevant as conscious sedation becomes standard.
  • Last updated: 2026-04-16
• SAVI-AVR Trial (Protocol published)
  • Prospective non-randomized comparison of sutureless vs. stented aortic valve replacement. Addresses optimization within the surgical pathway.
• NHLBI Advanced Cardiac CT Reconstruction (NCT05372627)
  • Status: Not yet recruiting | Enrollment: 1,000 | Sponsor: NHLBI
  • Advanced CT reconstruction — relevant for pre-TAVR imaging optimization.
  • Last updated: 2026-04-22

Mitral Valve — Repair

• [LANDMARK] REPAIR-MR (MitraClip vs. Surgery for Primary MR) (NCT04198870)
  • Status: Active, not recruiting | Enrollment: 500 | Sponsor: Abbott Medical Devices
  • Significance: The definitive trial comparing TEER with surgical repair for primary MR. Results will determine whether TEER can challenge surgery's Class I standing in operable patients. Currently, TEER for primary MR is Class IIa in both guidelines, restricted to high-surgical-risk patients. This trial could reshape the landscape.
  • Last updated: 2025-11-12
• [LANDMARK] PRIMATY (MitraClip vs. Surgery for Secondary MR) (NCT05051033)
  • Status: Recruiting | Enrollment: 450 | Sponsor: Annetine Gelijns
  • Significance: Compares transcatheter mitral repair with surgery for secondary MR — the first head-to-head surgical comparison in this population. Results will address whether the ESC 2025 Class I recommendation for TEER (based on COAPT) should extend to or be compared with surgical alternatives.
  • Last updated: 2026-03-03
• [LANDMARK] COAPT — Long-Term Follow-Up (NCT03706833)
  • Status: Active, not recruiting | Enrollment: 1,247 | Sponsor: Edwards Lifesciences (PASCAL arm added)
  • Significance: The foundational trial for TEER in ventricular secondary MR, now with PASCAL system arm and extended follow-up. 5-year data confirmed sustained benefit; longer follow-up will address durability questions.
  • Last updated: 2026-04-09
• MitraClip G5 Registry (NCT07543874) — New trial
  • Status: Not yet recruiting | Enrollment: 1,000 | Sponsor: University Hospital of Cologne
  • Real-world registry for the next-generation MitraClip G5 system. Will capture early experience with iterative device improvements.
  • Last updated: 2026-04-22
• MITRA-REVERSE (CMR Assessment of Remodeling After MitraClip) (NCT02924363)
  • Status: Completed | Enrollment: 54 | Sponsor: Dipan Shah
  • CMR-based evaluation of reverse cardiac remodeling post-MitraClip. Results pending publication.
  • Last updated: 2026-04-20

Mitral Valve — Replacement

• [LANDMARK] Intrepid TMVR Pivotal (NCT03242642)
  • Status: Recruiting | Enrollment: 1,056 | Sponsor: Medtronic Cardiovascular
  • Significance: The largest ongoing TMVR pivotal trial. Intrepid represents Medtronic's major bet on transcatheter mitral replacement — a technically demanding but potentially transformative therapy for patients with severe MR unsuitable for repair. Slow enrollment has been a concern.
  • Last updated: 2026-03-31

Tricuspid Valve — Repair

• [LANDMARK] TRILUMINATE Pivotal (TriClip for TR) (NCT03904147)
  • Status: Active, not recruiting | Enrollment: 572 | Sponsor: Abbott Medical Devices
  • Significance: The trial that led to TriClip FDA approval and formed a cornerstone of the ESC 2025 Class IIa recommendation for transcatheter TR treatment. Longer-term follow-up data will be crucial for assessing durability of benefit and informing future guideline updates.
  • Last updated: 2024-12-19
• [LANDMARK] CLASP II TR (PASCAL for TR) (NCT04097145)
  • Status: Recruiting | Enrollment: 870 | Sponsor: Edwards Lifesciences
  • Significance: Edwards' PASCAL system for tricuspid TEER — competing directly with Abbott's TriClip. Enrollment expansion to 870 reflects the growing commercial importance of the tricuspid space.
  • Last updated: 2026-04-06
• TRAIPTA (Trans-Atrial Intra-Pericardial Tricuspid Annuloplasty) (NCT06479824)
  • Status: Suspended | Enrollment: 60 | Sponsor: NHLBI/Cook
  • Novel transcatheter annuloplasty approach — suspension warrants monitoring for safety signals vs. logistical issues.
  • Last updated: 2026-04-17

Tricuspid Valve — Replacement

• [LANDMARK] TRISCEND II (EVOQUE Tricuspid Replacement) (NCT04482062)
  • Status: Active, not recruiting | Enrollment: 864 | Sponsor: Edwards Lifesciences
  • Significance: The pivotal trial for EVOQUE, the first transcatheter tricuspid valve replacement. FDA-approved based on these data. Real-world registry data (TVT Registry, 1,034 patients) reported today mirror the trial results, providing early generalizability evidence.
  • Last updated: 2026-02-27
• TRICENTO G2 First-in-Man (NCT07536724) — New trial
  • Status: Not yet recruiting | Enrollment: 10 | Sponsor: Medira GmbH
  • First-in-human study of a novel transcatheter tricuspid valve replacement system — the tricuspid replacement space continues to attract new entrants beyond EVOQUE.
  • Last updated: 2026-04-17

Other

• Preoperative Dental Screening Before Valve Surgery/TAVI (NCT07511673)
  • Status: Not yet recruiting | Enrollment: 1,300 | Sponsor: Region Skane
  • Randomized study of dental screening before valve procedures — addressing the endocarditis prevention question from an often-overlooked angle.
  • Last updated: 2026-04-22
• EasyCross Device (Self-Centering Catheter) (NCT06412354)
  • Status: Completed | Enrollment: 20 | Sponsor: Vivheart s.r.l.
  • First-in-human study of a self-centering catheter for aortic valve crossing — relevant accessory technology for TAVR procedures.
  • Last updated: 2026-04-22

---

Social & Conference Highlights

No major conference proceedings today. The structural heart community's attention is focused on tomorrow's Edwards Lifesciences earnings call, which typically includes clinical program updates alongside financial results. The TVARC-2 publication in JACC is likely to generate significant discussion on #CardioTwitter — particularly around how standardized endpoints will reshape the tricuspid trial landscape and the implicit tension between repair and replacement platforms.

---

Looking ahead: Edwards Lifesciences Q1 2026 earnings tomorrow will be the week's marquee event. Beyond the financial numbers, listen for updates on PASCAL/EVOQUE adoption metrics and any commentary on the commercial impact of ESC 2025 guideline changes. The TVARC-2 framework published today sets the stage for the next generation of tricuspid trials — watch for industry response as Abbott and Edwards position TriClip and PASCAL/EVOQUE for head-to-head comparisons that could define market share for years to come.

— E. Nolan Beckett | The Valve Wire